A novel therapeutic target Vasohibin-2
For the treatment of refractory cancers including pancreatic cancer
Overview
Vasohibin-2 (referred to as VASH2) knockdown significantly reduced metastasis of pancreatic cancer cells (Fig. 1) and prolonged survival period after orthotopic transplantation (Fig.2). The mechanisms of action are;
(1)VASH2 knockdown reduces cancer cell invasion through suppressing of tubulin carboxypeptidase activity within the cell.
(2) VASH2 secreted by cancer cells stimulates tumor angiogenesis, so when VASH2 was knocked down, tumor angiogenesis was prevented.
(3) VASH2 regulates the production of inflammatory chemokines and cytokines in cancer cells, which in turn, accelerates the recruitment of MDSC and TAM and prevents the infiltration of cytotoxic T lymphocytes. The inhibition of VASH2 eliminates immune suppression in pancreatic cancer.
Inhibition of Vasohibin-2 expression Ref. [1]
Product Application
・Antibody drug or peptide vaccine targeting VASH2 for the treatment of cancer which highly express VASH-2.
(e.g. pancreatic/ovarian/esophageal cancer)
Related Works
[1] Iida‐Norita R, Kawamura M, Suzuki Y, et al. Vasohibin‐2 plays an essential role in metastasis of pancreatic ductal adenocarcinoma. Cancer Sci. 2019;110:2296–2308.
IP Data
IP No. ： WO2019/045025 WO2014/087810
Inventor ： SATO Yasufumi
keyword ： Medical drug(including research tools)
Novel therapeutic target Vasohibin-2
For the treatment of refractory cancers including pancreatic cancer
Anti-Vasohibin-2 antibody comparison with bevacizumab Ref. [1]
Peptide Vaccine Ref. [WO2019/045025]
Product Application
・Recurrence prevention of VASH2 high expression cancer
・VASH2 high expression cancer metastasis inhibitor
Related Works
[1] Koyanagi T, Suzuki Y, Komori K, et al. Targeting human vasohibin-2 by a neutralizing monoclonal antibody for anti-cancer treatment. Cancer Sci. 2017;108:512–519.
IP Data
IP No. ： WO2019/045025 WO2014/087810
Inventor ： SATO Yasufumi
keyword ： Medical drug(including research tools)